News Image

NASDAQ:GMAB, a strong growth stock, setting up for a breakout.

By Mill Chart

Last update: Nov 1, 2023

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if GENMAB A/S -SP ADR (NASDAQ:GMAB) is suited for growth investing, while it is forming a base and may be ready to breakout. Investors should of course do their own research, but we spotted GENMAB A/S -SP ADR showing up in our growth with base formation screen, so it may be worth spending some more time on it.

Growth Examination for NASDAQ:GMAB

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:GMAB has achieved a 8 out of 10:

  • GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.97%, which is quite good.
  • GMAB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 36.32% yearly.
  • GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.29%.
  • GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.90% yearly.
  • The Earnings Per Share is expected to grow by 17.80% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 16.99% on average over the next years. This is quite good.

Health Insights: NASDAQ:GMAB

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:GMAB scores a 8 out of 10:

  • GMAB has an Altman-Z score of 27.08. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
  • GMAB's Altman-Z score of 27.08 is amongst the best of the industry. GMAB outperforms 96.83% of its industry peers.
  • GMAB has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.14, GMAB belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
  • GMAB has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • A Current Ratio of 14.93 indicates that GMAB has no problem at all paying its short term obligations.
  • GMAB has a Current ratio of 14.93. This is amongst the best in the industry. GMAB outperforms 86.31% of its industry peers.
  • A Quick Ratio of 14.90 indicates that GMAB has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 14.90, GMAB belongs to the best of the industry, outperforming 86.31% of the companies in the same industry.

What does the Profitability looks like for NASDAQ:GMAB

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:GMAB, the assigned 7 is noteworthy for profitability:

  • With an excellent Return On Assets value of 14.85%, GMAB belongs to the best of the industry, outperforming 98.16% of the companies in the same industry.
  • GMAB has a better Return On Equity (16.52%) than 96.49% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 16.77%, GMAB belongs to the top of the industry, outperforming 98.66% of the companies in the same industry.
  • GMAB had an Average Return On Invested Capital over the past 3 years of 17.24%. This is significantly above the industry average of 12.13%.
  • GMAB has a Profit Margin of 29.02%. This is amongst the best in the industry. GMAB outperforms 97.16% of its industry peers.
  • Looking at the Operating Margin, with a value of 39.90%, GMAB belongs to the top of the industry, outperforming 98.66% of the companies in the same industry.

How do we evaluate the setup for NASDAQ:GMAB?

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:GMAB scores a 7 out of 10:

GMAB has a bad technical rating, but it does show a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is very little resistance above the current price. There is a support zone below the current price at 28.39, a Stop Loss order could be placed below this zone.

Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.

Our latest full fundamental report of GMAB contains the most current fundamental analsysis.

Our latest full technical report of GMAB contains the most current technical analsysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

GENMAB A/S -SP ADR

NASDAQ:GMAB (4/26/2024, 7:00:00 PM)

After market: 28.15 0 (0%)

28.15

+0.69 (+2.51%)

GMAB News

News Image3 days ago - Investor's Business DailyWhy Big Pharma Is Following Novartis' Lead In A $25 Billion Market

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

News Image17 days ago - ChartmillNASDAQ:GMAB is not too expensive for the growth it is showing.

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

News Image25 days ago - Investor's Business DailyGenmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Genmab is buying a privately held company focused on antibody drug conjugates.

News Image25 days ago - Genmab A/SGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
News Image2 months ago - Genmab A/SU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
News Image2 months ago - Seeking AlphaAbbVie/ Genmab win FDA priority review for lymphoma therapy (NYSE:ABBV)

Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.

News Image2 months ago - Seeking AlphaBMO upgrades Genmab to outperform, cites diversification potential (NASDAQ:GMAB)

BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term

News Image2 months ago - Seeking AlphaGenmab reports FY results (NASDAQ:GMAB)

Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...

GMAB Links
Follow us for more